The Kroger Co.
KR
Dollar General
DG
The GEO Group Inc
GEO
Tractor Supply
TSCO
Occidental Petroleum
OXY
US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 63.820
- -1.020-1.57%
Close Mar 26 16:00 ET
- 62.900
- -0.920-1.44%
Post 20:01 ET
7.88BMarket Cap18.61P/E (TTM)
65.030High63.205Low1.28MVolume65.030Open64.840Pre Close81.81MTurnover1.05%Turnover Ratio18.61P/E (Static)123.53MShares66.00052wk High21.67P/B7.80BFloat Cap37.73052wk Low--Dividend TTM122.14MShs Float66.000Historical High--Div YieldTTM2.82%Amplitude1.410Historical Low63.714Avg Price1Lot Size
Halozyme Therapeutics News
Should You Be Adding Halozyme Therapeutics (NASDAQ:HALO) To Your Watchlist Today?
Artisan Small Cap Fund Reduced Its Stake in Halozyme Therapeutics (HALO). Here's Why
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $67
AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More. -- Barrons.com
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeuticsto Buy
Halozyme Therapeutics Analyst Ratings
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $78
It is reported that Halozyme Therapeutics (HALO.US) will engage in a patent battle with Merck (MRK.US) over the injectable version of Keytruda.
According to reports, Halozyme Therapeutics (HALO.US) and Merck (MRK.US) are brewing a new patent dispute, with the focus of the controversy on the injectable version of the blockbuster cancer drug Keytruda.
Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version
New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ
Merck Has Challenged Halozyme's Patents for Enzyme to Inject Drugs That Had Been Given Intravenously -- WSJ
Halozyme Believes Merck's Subcutaneous Keytruda Infringes Patents, Sources Say -- WSJ
Halozyme Planning to Say Wednesday That Merck Needs to License Its Technology, Sources Say -- WSJ
Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly
Halozyme Therapeutics Insider Sold Shares Worth $1,260,681, According to a Recent SEC Filing
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $75
Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Raises Target Price to $60
Market Insights
Donald Trump Donald Trump
Trump-Election Stocks refer to securities closely associated with business dealings, political actions, or events related to Donald Trump. Trump-Election Stocks refer to securities closely associated with business dealings, political actions, or events related to Donald Trump.